Pyrimidine inhibitors synergize with nucleoside analogues to block SARS-CoV-2.
Adenosine Monophosphate
/ analogs & derivatives
Alanine
/ analogs & derivatives
Antiviral Agents
/ pharmacology
COVID-19
/ virology
Cell Line
Cytidine
/ analogs & derivatives
Drug Evaluation, Preclinical
Humans
Hydroxylamines
Nucleosides
/ analogs & derivatives
Pyrimidines
/ pharmacology
SARS-CoV-2
/ drug effects
COVID-19 Drug Treatment
Journal
Nature
ISSN: 1476-4687
Titre abrégé: Nature
Pays: England
ID NLM: 0410462
Informations de publication
Date de publication:
04 2022
04 2022
Historique:
received:
22
10
2021
accepted:
26
01
2022
pubmed:
8
2
2022
medline:
16
4
2022
entrez:
7
2
2022
Statut:
ppublish
Résumé
The SARS-CoV-2 virus has infected more than 261 million people and has led to more than 5 million deaths in the past year and a half
Identifiants
pubmed: 35130559
doi: 10.1038/s41586-022-04482-x
pii: 10.1038/s41586-022-04482-x
pmc: PMC10377386
mid: NIHMS1876921
doi:
Substances chimiques
Antiviral Agents
0
Hydroxylamines
0
Nucleosides
0
Pyrimidines
0
remdesivir
3QKI37EEHE
Adenosine Monophosphate
415SHH325A
Cytidine
5CSZ8459RP
pyrimidine
K8CXK5Q32L
Alanine
OF5P57N2ZX
molnupiravir
YA84KI1VEW
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
134-140Subventions
Organisme : NIAID NIH HHS
ID : R01 AI074951
Pays : United States
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : NIAID NIH HHS
ID : T32 AI007524
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI140539
Pays : United States
Organisme : Intramural NIH HHS
ID : ZIA TR000414
Pays : United States
Organisme : NIAID NIH HHS
ID : R21 AI151882
Pays : United States
Organisme : Bill & Melinda Gates Foundation
ID : INV-016638
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI150246
Pays : United States
Organisme : NIAID NIH HHS
ID : R21 AI158134
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI152362
Pays : United States
Organisme : NIAID NIH HHS
ID : R21 AI153480
Pays : United States
Organisme : Bill & Melinda Gates Foundation
ID : INV-018479
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI122749
Pays : United States
Commentaires et corrections
Type : UpdateOf
Type : CommentIn
Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Nature Limited.
Références
Lu, R. et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 395, 565–574 (2020).
doi: 10.1016/S0140-6736(20)30251-8
pubmed: 32007145
pmcid: 7159086
Huang, C. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395, 497–506 (2020).
pubmed: 31986264
pmcid: 7159299
Huchting, J. Targeting viral genome synthesis as broad-spectrum approach against RNA virus infections. Antivir. Chem. Chemother. 28, 2040206620976786 (2020).
doi: 10.1177/2040206620976786
pubmed: 33297724
pmcid: 7734526
Jordheim, L. P., Durantel, D., Zoulim, F. & Dumontet, C. Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases. Nat. Rev. Drug Discov. 12, 447–464 (2013).
doi: 10.1038/nrd4010
pubmed: 23722347
Sheahan, T. P. et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat. Commun. 11, 222 (2020).
doi: 10.1038/s41467-019-13940-6
pubmed: 31924756
pmcid: 6954302
Agostini, M. L. et al. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. mBio 9, e00221-18 (2018).
doi: 10.1128/mBio.00221-18
pubmed: 29511076
pmcid: 5844999
Pruijssers, A. J. et al. Remdesivir inhibits SARS-CoV-2 in human lung cells and chimeric SARS-CoV expressing the SARS-CoV-2 RNA polymerase in mice. Cell Rep. 32, 107940 (2020).
doi: 10.1016/j.celrep.2020.107940
pubmed: 32668216
pmcid: 7340027
Sheahan, T. P. et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci. Transl. Med. 9, eaal3653 (2017).
doi: 10.1126/scitranslmed.aal3653
pubmed: 28659436
pmcid: 5567817
Dittmar, M. et al. Drug repurposing screens reveal cell-type-specific entry pathways and FDA-approved drugs active against SARS-Cov-2. Cell Rep. 35, 108959 (2021).
doi: 10.1016/j.celrep.2021.108959
pubmed: 33811811
pmcid: 7985926
Janes, J. et al. The ReFRAME library as a comprehensive drug repurposing library and its application to the treatment of cryptosporidiosis. Proc. Natl Acad. Sci. USA 115, 10750–10755 (2018).
doi: 10.1073/pnas.1810137115
pubmed: 30282735
pmcid: 6196526
Bakowski, M. A. et al. Drug repurposing screens identify chemical entities for the development of COVID-19 interventions. Nat. Commun. 12, 3309 (2021).
doi: 10.1038/s41467-021-23328-0
pubmed: 34083527
pmcid: 8175350
Riva, L. et al. Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing. Nature 586, 113–119 (2020).
doi: 10.1038/s41586-020-2577-1
pubmed: 32707573
pmcid: 7603405
Yates, M. K. & Seley-Radtke, K. L. The evolution of antiviral nucleoside analogues: a review for chemists and non-chemists. Part II: complex modifications to the nucleoside scaffold. Antiviral Res. 162, 5–21 (2019).
doi: 10.1016/j.antiviral.2018.11.016
pubmed: 30529089
Sheahan, T. P. et al. An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci. Transl. Med. 12, eabb5883 (2020).
doi: 10.1126/scitranslmed.abb5883
pubmed: 32253226
Jordan, P. C. et al. Initiation, extension, and termination of RNA synthesis by a paramyxovirus polymerase. PLoS Pathog. 14, e1006889 (2018).
doi: 10.1371/journal.ppat.1006889
pubmed: 29425244
pmcid: 5823471
Tchesnokov, E. P., Feng, J. Y., Porter, D. P. & Gotte, M. Mechanism of inhibition of Ebola virus RNA-dependent RNA polymerase by remdesivir. Viruses 11, 326 (2019).
doi: 10.3390/v11040326
pmcid: 6520719
Agostini, M. L. et al. Small-molecule antiviral β-D-N
doi: 10.1128/JVI.01348-19
pubmed: 31578288
pmcid: 6880162
Urakova, N. et al. β-D-N
doi: 10.1128/JVI.01965-17
pubmed: 29167335
pmcid: 5774879
Ma, J. & Motsinger-Reif, A. Current methods for quantifying drug synergism. Proteom. Bioinform. 1, 43–48 (2019).
pubmed: 32043089
pmcid: 7010330
Ariav, Y., Ch'ng, J. H., Christofk, H. R., Ron-Harel, N. & Erez, A. Targeting nucleotide metabolism as the nexus of viral infections, cancer, and the immune response. Sci. Adv. 7, eabg6165 (2021).
doi: 10.1126/sciadv.abg6165
pubmed: 34138729
pmcid: 8133749
Wahl, A. et al. SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801. Nature 591, 451–457 (2021).
doi: 10.1038/s41586-021-03312-w
pubmed: 33561864
pmcid: 7979515
Cox, R. M., Wolf, J. D. & Plemper, R. K. Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets. Nat. Microbiol. 6, 11–18 (2021).
doi: 10.1038/s41564-020-00835-2
pubmed: 33273742
Hou, Y. J. et al. SARS-CoV-2 reverse genetics reveals a variable infection gradient in the respiratory tract. Cell 182, 429–446.e14 (2020).
doi: 10.1016/j.cell.2020.05.042
pubmed: 32526206
pmcid: 7250779
Pizzorno, A. et al. Characterization and treatment of SARS-CoV-2 in nasal and bronchial human airway epithelia. Cell Rep. Med. 1, 100059 (2020).
doi: 10.1016/j.xcrm.2020.100059
pubmed: 32835306
pmcid: 7373044
Tyson, J. R. et al. Improvements to the ARTIC multiplex PCR method for SARS-CoV-2 genome sequencing using nanopore. Preprint at bioRxiv https://doi.org/10.1101/2020.09.04.283077 (2020).
Li, H. Minimap2: pairwise alignment for nucleotide sequences. Bioinformatics 34, 3094–3100 (2018).
doi: 10.1093/bioinformatics/bty191
pubmed: 29750242
pmcid: 6137996
Robinson, J. T. et al. Integrative genomics viewer. Nat. Biotechnol. 29, 24–26 (2011).
doi: 10.1038/nbt.1754
pubmed: 21221095
pmcid: 3346182